News Novartis grabs kidney drug developer Regulus in $1.7bn deal Novartis has grown in renal diseases once again with a $1.7bn deal to buy Regulus and its autosomal dominant polycystic kidney disease (ADPKD) drug.
News US gives $99m for Ebola jab project, as cases spread in Afri... As Africa's CDC chief warns "unprecedented" Ebola outbreak could spread to other parts of the world, the US awards R&D funding to an IAVI vaccine.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.